The Three Peptides
That Start It All
These are the three compounds that most commonly start that process. They're not new. They're not obscure. They solve real, specific problems — and the research behind each one is worth understanding properly before you make any decisions.
Photo / Pexels — free for commercial use
BPC-157 is a 15-amino-acid peptide derived from a protective protein found naturally in human gastric juice. It has been studied across a substantial body of preclinical research — more than 36 published studies from 1993 to 2024 — with a consistent focus on its effects on soft tissue healing, inflammation, and gut protection.[1]
The mechanisms behind it are reasonably well understood. BPC-157 promotes angiogenesis — the formation of new blood vessels into damaged tissue — by activating the VEGFR2-Akt-eNOS pathway. It upregulates fibroblast activity and collagen synthesis, particularly in tendons and ligaments, which are poorly vascularized and notoriously slow to heal. It has also shown anti-inflammatory properties and protective effects on the gut lining, including evidence of counteracting damage caused by NSAIDs.[2]
In preclinical models, BPC-157 has demonstrated consistently positive healing outcomes across muscle, tendon, ligament, and bone injury types — including accelerated Achilles tendon recovery with significantly improved biomechanical load-to-failure and functionality scores, and evidence of healing even in the presence of corticosteroids.[3] In a published human case series, 7 of 12 patients with chronic knee pain reported relief lasting more than six months following a single BPC-157 injection.[4] Human data remains limited: as of 2025, only three small pilot studies exist. No adverse events were reported in any of them.
The honest framing is this: the preclinical evidence base for BPC-157 is robust and spans three decades. The human evidence is early, with rigorous large-scale trials still lacking. The FDA classified it as a Category 2 bulk drug substance in 2023, which means it cannot be compounded commercially — a regulatory status that reflects the gap in human clinical evidence, not evidence of harm.[5] Many licensed physicians continue to offer it through compounding pharmacies operating outside that restriction. If you're considering it, the research is worth reading in full, and the guidance of a knowledgeable provider matters.
Retatrutide is a single peptide molecule that activates three hormone receptors simultaneously: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon. This triple-agonist mechanism is what separates it from the generation of weight loss drugs currently on the market — it targets appetite, insulin sensitivity, and energy expenditure through parallel pathways rather than one.[6]
Understanding why this works requires understanding what obesity actually is, biologically. It is not a failure of willpower. It is, in large part, a dysregulation of the hormonal signals that govern hunger, satiety, and fat storage. What retatrutide does — and what makes it categorically different from caloric restriction — is recalibrate those signals at the receptor level, reducing appetite while simultaneously increasing energy expenditure and improving insulin sensitivity.[7]
In the TRIUMPH-4 Phase 3 trial (68 weeks, 445 participants), retatrutide at 12 mg produced an average weight loss of 28.7% of body weight — equivalent to an average of 71.2 lbs. Every participant receiving the 8 mg or 12 mg doses in Phase 2 trials achieved at least 5% weight loss. Phase 2 data published in the New England Journal of Medicine showed 24.2% mean weight reduction at 48 weeks — results described as comparable in magnitude to bariatric surgery outcomes. The weight-loss curves had not plateaued at the end of the trial period.[8,9]
Retatrutide is not yet FDA-approved and is currently available through investigational or compounding channels only. Side effects are consistent with other GLP-1-class therapies: nausea, vomiting, and diarrhea — predominantly during dose escalation — and a newly identified signal of dysesthesia (abnormal touch sensitivity) observed in a minority of Phase 3 participants. As with any peptide therapy, working with a physician who can manage dosing and monitor response is essential.
The results of Phase 2 were described as comparable in magnitude to bariatric surgery — without the surgery. The weight-loss curves hadn't even plateaued when the 48-week trial ended.
NEJM Phase 2 Trial — Retatrutide for Obesity, 2023GHK-Cu is a naturally occurring copper-binding peptide. Levels are high in your twenties — when collagen is robust, wound healing is fast, and skin has its characteristic density — and decline steadily from there. By your forties, circulating GHK-Cu has dropped to a fraction of peak levels. The downstream effects show up as exactly what you'd expect: thinner skin, slower repair, reduced collagen remodeling.
What makes GHK-Cu scientifically interesting is the breadth of its biological activity. It doesn't just promote collagen — it regulates a wide range of skin repair genes, stimulates glycosaminoglycan synthesis (the compounds responsible for skin hydration and structure), promotes angiogenesis in wound tissue, and has demonstrated anti-inflammatory and antioxidant properties. In hair follicle research, it has been shown to enlarge follicle size and stimulate growth.[10]
Unlike many peptide therapies, GHK-Cu produces meaningful results when applied topically — because copper peptides are small enough to penetrate the dermal layer. Multiple double-blind clinical studies on GHK-Cu topical formulations have shown significant improvements in fine lines, skin laxity, density, and clarity, as well as accelerated wound healing in clinical settings. Topical application means injections are not required to see skin and hair outcomes — which makes it among the most accessible entry points into peptide therapy.[11]
GHK-Cu is what gets said about the expensive serums and creams — that they don't really work — because most of them contain vanishingly small concentrations of active compounds, stabilized poorly, and marketed on aspirational claims. GHK-Cu at therapeutic concentrations, in a properly formulated vehicle, is a different category entirely. The research behind it is extensive enough to distinguish it clearly from cosmetic noise.
What All Three Have in Common
Beyond the surface differences — injury repair, fat metabolism, skin biology — these three peptides share a structural logic that explains why they tend to convert skeptics.
BioRefined's research library covers each of these peptides in depth — the full mechanisms, the specific research, what to look for in a provider, and what questions to ask. These articles are written to give you a complete picture, not a sales pitch. The goal is that you understand what you're considering before you consider it.
Photo / Pexels — free for commercial use
The Bigger Picture
Peptides are not a shortcut. They are tools — compounds with specific mechanisms, specific evidence bases, specific appropriate uses, and specific limitations. The people who benefit most from them are not those chasing the next trend, but those who take the time to understand what they're working with and why.
What BPC-157, Retatrutide, and GHK-Cu represent collectively is a new category of biological leverage. Not magic. Not hype. Just science that has finally caught up to problems that conventional medicine often handles poorly — chronic soft tissue injury, metabolic obesity, age-related skin change — and compounds that offer a genuinely different mechanism of action.
The 12 vials in the fridge is a cliché because it keeps happening. Not because people are reckless, but because when something works — when you can feel the biology respond — the natural instinct is to keep learning.
That's exactly what BioRefined is here to help you do.
References
- 1Vasireddi N et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. Sports Health. 2025. Review of 36 studies from 1993–2024 on musculoskeletal effects, mechanism of action, metabolism, and safety profile. PMC12313605
- 2Rupa Health / BPC-157 Summary. Science-backed uses, benefits, dosage, and safety. Covers VEGFR2-Akt-eNOS angiogenesis pathway, fibroblast activity, gut mucosal protection, and NSAID interaction. rupahealth.com
- 3Gwyer D et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research. 2019;377(2):153–159. All reviewed studies demonstrated consistently positive healing effects. doi:10.1007/s00441-019-03016-8
- 4Lee E, Padgett B. Intra-articular injection of BPC-157 for multiple types of knee pain. Alt Ther Health Med. 2021. 7 of 12 patients reported pain relief lasting over 6 months after a single injection. Cited in Arthroscopy Journal review, 2024. Arthroscopy Journal 2024
- 5FDA Category 2 bulk drug substance classification for BPC-157, 2023. Cited in Vasireddi et al., PMC12313605 and Prisk Orthopaedic & Wellness commentary, 2025.
- 6Eli Lilly. Retatrutide: Investigational GIP, GLP-1, and Glucagon Triple Hormone Receptor Agonist. TRIUMPH-4 Phase 3 trial press release, December 2025. investor.lilly.com
- 7Jastreboff AM et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514–526. Mechanism of action, Phase 2 efficacy and safety results. doi:10.1056/NEJMoa2301972
- 8Lilly TRIUMPH-4 Phase 3 results. 12 mg dose: 28.7% mean body weight reduction at 68 weeks; average 71.2 lbs lost. TRIUMPH-4 NCT05931367, December 2025.
- 9Sanyal AJ et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037–2048. 24.2% weight reduction at 48 weeks; weight-loss curves had not plateaued. doi:10.1038/s41591-024-03018-2
- 10BioRefined Editorial. The Peptide Your Skin Stops Making in Your 40s — GHK-Cu comprehensive review. March 2026. Covers collagen remodeling, glycosaminoglycan synthesis, hair follicle research, and gene regulation. biorefined.blog
- 11Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. GHK-Cu mechanisms: collagen, wound healing, anti-inflammatory, antioxidant, and hair follicle effects. PMC6073405
This article is for educational and informational purposes only and does not constitute medical advice, a diagnosis, or a treatment recommendation. BPC-157 is an investigational compound not approved by the FDA for human therapeutic use. Retatrutide is an investigational drug currently in Phase 3 clinical trials and is not yet FDA-approved. GHK-Cu is used in topical cosmetic formulations and in investigational settings. Before pursuing any peptide therapy, consult a qualified healthcare provider. BioRefined does not diagnose, treat, or prescribe.